May 13, 2013
Yakult Honsha’s pharmaceutical sales were down 5.8% from a year earlier to 37,072 million yen in FY2012 ended March 2013, due to a sales decline of the anti-malignant tumor agent Elplat (oxaliplatin) resulting from last year’s NHI price revision, according...read more